Determination of serum levels of imatinib mesylate in patients with chronic myeloid leukemia: validation and application of a new analytical method to monitor treatment compliance.

Item

http://www.wikidata.org/entity/Q41501849

description

2013 nî lūn-bûn

@nan

2013年の論文

@ja

2013年論文

@yue

2013年論文

@zh-hant

2013年論文

@zh-hk

2013年論文

@zh-mo

2013年論文

@zh-tw

2013年论文

@wuu

2013年论文

@zh

2013年论文

@zh-cn

name

Determination of serum levels ...... monitor treatment compliance.

@en

type

Item

label

Determination of serum levels ...... monitor treatment compliance.

@en

prefLabel

Determination of serum levels ...... monitor treatment compliance.

@en

P1476

Determination of serum levels ...... o monitor treatment compliance

@en

P2093

Ariane Julio Rivellis

http://www.w3.org/2001/XMLSchema#string

Ariel Lais de Lima Costa

http://www.w3.org/2001/XMLSchema#string

Dalton de Alencar Fisher Chamone

http://www.w3.org/2001/XMLSchema#string

Luciana Nardinelli

http://www.w3.org/2001/XMLSchema#string

Mafalda Megumi Yoshinaga Novaes

http://www.w3.org/2001/XMLSchema#string

Melissa Medrano Gomes

http://www.w3.org/2001/XMLSchema#string

Vinícius Marcondes Rezende

http://www.w3.org/2001/XMLSchema#string

P2860

Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia

Quantification of the anti-leukemia drug STI571 (Gleevec) and its metabolite (CGP 74588) in monkey plasma using a semi-automated solid phase extraction procedure and liquid chromatography-tandem mass spectrometry.

Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet.

Imatinib therapy in chronic myelogenous leukemia: strategies to avoid and overcome resistance.

Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results.

Plasma exposure of imatinib and its correlation with clinical response in the Tyrosine Kinase Inhibitor Optimization and Selectivity Trial.

Important therapeutic targets in chronic myelogenous leukemia.

Chronic myeloid leukemia: an update of concepts and management recommendations of European LeukemiaNet.

The role of therapeutic drug monitoring of imatinib in patients with chronic myeloid leukemia and metastatic or unresectable gastrointestinal stromal tumors.

Current treatment strategies in chronic myeloid leukemia.

P304

103-108

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.5581/1516-8484.20130030

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Israel Bendit

Felipe Augusto Dörr

P577

2013-01-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

237060947

http://www.w3.org/2001/XMLSchema#string

P698

23741187

http://www.w3.org/2001/XMLSchema#string

P921

chronic myeloid leukemia

P932

3672119

http://www.w3.org/2001/XMLSchema#string